ENO1 and non-small cell lung carcinoma: Kaplan-Meier survival analysis reveals that NSCLC patients with a higher increase of anti-ENO1 Ab (≥12%), a tumor volume less than the median value (≤5 cm3), diagnosis of early stages (stage I/II), and adenocarcinoma subtype of lung cancer, have a significantly better 2-year DFS (Log Rank test; P = 0.009, P = 0.001, P = 0.023 and P = 0.001 respectively; Figure 2C–2F).